Sanofi - ADR (SNY) News

Sanofi - ADR (SNY): $44.81

0.98 (+2.24%)

POWR Rating

Component Grades













Filter SNY News Items

SNY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SNY News Highlights

  • SNY's 30 day story count now stands at 104.
  • Over the past 25 days, the trend for SNY's stories per day has been choppy and unclear. It has oscillated between 2 and 21.
  • The most mentioned tickers in articles about SNY are DRUG, GSK and REGN.

Latest SNY News From Around the Web

Below are the latest news stories about Sanofi that investors may wish to consider to help them evaluate SNY as an investment opportunity.

Drugmakers Seek Emergency Authorization For New COVID Vaccine

Watch Video European drugmakers Sanofi and Glaxosmithkline (GSK) released data showing their COVID vaccine is 100% effective at keeping patients out of the hospital. It has not been independently scientifically reviewed. Drugmakers Sanofi and GlaxoSmithKline have asked the Food and Drug Administration for emergency use authorization of their vaccine. "We are confident that this vaccine can play an important role as we continue to address this pandemic and prepare for the post-pandemic period," Roger Connor, president of GSK, said in a statement. Sanofi''s and GSK''s vaccine is based on a more conventional protein-based vaccine technology. It''s a recombinant protein vaccine, which means it recombines different segments of DNA. This uses DNA from the SARS-COV-2 spike protein, which COVID...

Newsy | February 25, 2022

Canada Approves First Plant-Based COVID-19 Vaccine

As Sanofi SA (NASDAQ: SNY ) and GlaxoSmithKline Plc''s (NYSE: GSK ) COVID-19 vaccine finally heads to regulators, another shot using GSK''s pandemic adjuvant has won its first global approval . Mitsubishi Tanabe Pharma Corporation -backed Medicago''s recombinant COVID-19 vaccine, dubbed Covifenz, has snagged a green light in Canada in individuals 18 to 64 years of age. The vaccine uses a plant-based virus-like particles technology to mimic … Full story available on

Benzinga | February 25, 2022

Pharma Stock Roundup: GSK, SNY Face Pipeline Setbacks, AZN Cancer Study Meets Goals

Glaxo (GSK) and Sanofi (SNY) announce pipeline setbacks. AstraZeneca's (AZN) HER2-low metastatic breast cancer study on Enhertu succeeds.

Yahoo | February 25, 2022

France''s Sanofi to seek Covid vaccine approval after months of delays

French pharmaceuticals giant Sanofi has said that its Covid-19 vaccine, developed with Britain''s GlaxoSmithKline, had delivered positive results after nearly a year of setbacks that left it lagging far behind its rivals.

Radio France Internationale | February 24, 2022

Sanofi, GSK say vaccine shows 100% efficacy against hospitalization due to severe disease: Live COVID updates

Sanofi and GSK seek approval for a vaccine they say shows 100% efficacy against hospitalization due to severe disease in human trials. COVID updates.

Azcentral | February 24, 2022

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

No summary available.

Seeking Alpha | February 24, 2022

Sanofi-GSK plan to seek regulatory nod for COVID-19 vaccine

Sanofi (NASDAQ:SNY) and GlaxoSmithKline (NYSE:GSK) are planning to seek regulatory authorization for a COVID-19 vaccine. The companies intend to submit data from their booster and phase 3 efficacy trials as the basis for regulatory applications. The Sanofi-GSK vaccine is a refrigerator temperature-stable adjuvanted protein-based vaccine. Sanofi provides its recombinant antigen and GSK contributes its...

Seeking Alpha | February 23, 2022

New 2-dose vax shows 100% efficacy against severe Covid

Europe News: PARIS: French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their Covid-19 vaccine to be used as a boos.

The Times of India | February 23, 2022

Sanofi has new coronavirus vaccine candidate that’s 100% effective against severe disease, hospitalizations

The Sanofi-GSK vaccine can be used as a booster for other vaccines, including the Pfizer and Moderna mRNA vaccines. In the trials, the Sanofi-GSK booster vax increased neutralizing antibodies by 18- to 30-fold.

Boston Herald | February 23, 2022

New COVID vaccine results indicate 100% efficacy against severe disease

Using a conventional approach, a new COVID vaccine showed 100% efficacy against severe disease and hospitalizations, and it could be an effective booster after other COVID shots, the vaccine’s manufacturers announced on February 23. The vaccine, manufactured by the pharmaceutical companies Sanofi and GSK, showed a 75% efficacy against mild-to-moderate disease and showed a 55% efficacy against any symptomatic COVID-19 disease in the VAT08 Phase 3 trial. While the efficacy of the mRNA vaccines was lower than that observed in the original Biotech and Moderna vaccines, the companies noted it was still “in line with what can be expected in today’s environment dominated by variants of concern.” Following vaccination with one of the other Covid vaccines, the global VAT02 booster trial confirme...

Hespress English | February 23, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1259 seconds.